Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that patients with alopecia areata taking ritlecitinib reported higher satisfaction with hair growth after 24 and 48 weeks compared to those taking a placebo, aligning with improvements in hair growth noted by doctors.

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.

RADA16-I can effectively deliver and release mangiferin, improving its solubility and bioavailability.

This study found that melatonin may enhance hair follicle stem cell viability by downregulating the nuclear receptor RORA, which otherwise inhibits cell proliferation and promotes apoptosis.

This article discusses the clinical features, diagnosis, and management of acute radiation syndrome, using a case of a boy exposed to radioactive material in the desert, but reports no new research findings.

This article discusses the paradoxical effects of valproic acid on hair, reporting both drug-induced hair loss and the potential for hair growth when used topically, but presents no original research findings.

This study found that concurrent chemotherapy with radiotherapy may increase the risk of grade 2 persistent radiation-induced alopecia, while topical minoxidil showed potential benefits, though more research is needed on its efficacy.

This study found that ritlecitinib 50 mg is cost-effective compared to no treatment for patients in Japan with alopecia areata and significant scalp hair loss, demonstrating an incremental cost-effectiveness ratio below the country's cost-effectiveness threshold.

This study found that an optimal combination of ethnomedicinal extracts from East Nusa Tenggara, Indonesia, significantly increased hair length in mice, suggesting potential as a natural agent for hair growth through antioxidant mechanisms.

This study found that Rac1 activity in specific skin compartments is sufficient for hair formation, but results in hair with altered structure and pigmentation compared to normal.

This meta-analysis reports that ritlecitinib significantly improved hair growth in alopecia areata patients compared to placebo, although its potential requires further clinical exploration.

This study found that ritlecitinib, taken daily, led to scalp, eyebrow, and eyelash hair regrowth in patients aged 12 and older with severe and very severe alopecia areata over a 24-month period.

This case report describes a young female with Rhupus syndrome, characterized by symptoms of both Systemic Lupus Erythematosus and Rheumatoid Arthritis, who achieved clinical remission with treatment.

This study found that after 15 months of treatment with ritlecitinib, patients with alopecia areata and less than 95% initial hair loss experienced significant hair regrowth, though those with more extensive hair loss showed more variable improvement.

This dissertation demonstrates that FERONIA regulates essential plant functions such as RAC/ROP signaling, pollen tube reception, cell wall integrity, and sugar signaling as a cell surface receptor kinase.

This study found that Ritlecitinib significantly reduced hair loss in patients with alopecia areata by lowering SALT scores at weeks 12 and 24 compared to placebo, with acceptable safety but increased minor side effects like headaches and acne.

This study found that ritlecitinib, approved for alopecia areata in patients aged 12 and older, has an acceptable safety profile with mild to moderate side effects and no increase in serious adverse events compared to placebo.

This study found that hair treatment materials commonly used in Iraq and from international sources had radon, radium, and uranium concentration levels below international safety limits, suggesting they are safe for use.

This study describes characteristics and outcomes for adults initiating ritlecitinib for severe alopecia areata, highlighting increased hair regrowth and physician satisfaction with longer treatment durations, despite ongoing psychosocial impacts like embarrassment and anxiety among patients.

This study found that RAR-gamma 1 mRNA is present in multiple skin layers and structures, suggesting a role in maintaining and differentiating normal epidermis and skin appendages.

This study identified a large deletion in the desmoglein 4 gene as the genetic basis of the Iffa Credo "hairless" rat's skin phenotype, linking it to lanceolate hair mutations.

This review discusses how 5α-reductase inhibitors affect PSA levels in benign prostatic hyperplasia treatment and their role in prostate cancer screening, but reports no new clinical findings.

This study found that the enzyme encoded by Dgat1 acts as a retinol acyltransferase in murine epidermis, protecting against retinoid toxicity and alopecia by preventing retinol accumulation.

This review summarizes the composition, bioactive functions, and potential industrial applications of rice bran polysaccharides, focusing on how extraction methods and modifications impact their biological activities.

This study found that the treatment group experienced a higher average increase in hair counts than the placebo group, but the difference was not statistically significant.

This study identifies Armadillo Repeat Only proteins as crucial regulators of plant CNGC channels, influencing various plant functions and showcasing a unique plant-specific role in Ca2+ signaling.

This case report describes a 7-year-old girl who developed radiation-induced alopecia after a neurointerventional procedure, with dermoscopy revealing specific hair and scalp patterns that helped diagnose this rare complication. The findings highlight the importance of dermoscopy in distinguishing RIA from other alopecic disorders in children.

This study highlights that a novel radially aligned nanofiber scaffold with dual growth factor gradients significantly enhances wound healing, promoting cell migration, epidermal regeneration, and angiogenesis, ultimately leading to improved wound closure, immune regulation, and tissue remodeling compared to other groups.

This study suggests that PRX01, PRX44, and PRX73 regulate extensin-mediated cell wall properties during root hair cell growth, influencing growth patterns, peroxidase activity, and cell wall thickness.

In this phase 2b/3 trial, ritlecitinib showed effectiveness in treating alopecia areata patients with varying hair loss profiles, significantly improving patient-reported outcomes for hair regrowth and satisfaction compared to placebo, regardless of the hair loss type and extent at baseline.